Financhill
Back

CytoMed Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
75

GDTC
CytoMed Therapeutics

Last Price:
2.49
Seasonality Move:
3.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

CytoMed Therapeutics Price Quote

$2.49
-0.13 (0.27%)
(Updated: November 6, 2024 at 5:11 AM ET)

CytoMed Therapeutics Key Stats

Buy
75
CytoMed Therapeutics (GDTC) is a Buy

Day range:
$2.41 - $2.83
52-week range:
$1.20 - $5.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.04%

Volume:
53.8K
Avg. volume:
21.6K
1-year change:
-35.23%
Market cap:
$30.3M
Revenue:
$0
EPS:
$-0.19

How Much Does CytoMed Therapeutics Make?

Data Unavailable

Is CytoMed Therapeutics Growing As A Company?

Data Unavailable

CytoMed Therapeutics Stock Price Performance

What Is CytoMed Therapeutics 52-Week High & Low?

CytoMed Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy CytoMed Therapeutics?

Is CytoMed Therapeutics Cash Flow Positive?

  • What Is GDTC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$1.9M
  • What Is CytoMed Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$22.2K
  • What Is CytoMed Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $554K

CytoMed Therapeutics Return On Invested Capital

Data Unavailable

CytoMed Therapeutics Earnings Date & Stock Price

CytoMed Therapeutics Competitors

CytoMed Therapeutics Dividend Yield

CytoMed Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.00
Upside from Last Price: 90.61%

Major Shareholders

  • How many GDTC shares are owned by institutional investors?
    4.9K GDTC shares are owned by institutional investors
  • How many GDTC shares are owned by insiders?
    681.8K GDTC shares are owned by insiders